<DOC>
	<DOCNO>NCT02245360</DOCNO>
	<brief_summary>To investigate immunologic effect safety 60-day treatment Standardized Quality unit ( SQ ) grass Sublingual immunotherapy ( SLIT ) -tablet adult subject grass pollen-induced allergic rhinoconjunctivitis double-blind , placebo-controlled study .</brief_summary>
	<brief_title>Study Immunology Safety 60-day Treatment SQ Grass SLIT ( Sublingual Immunotherapy ) -Tablet Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>clinical history consistent grass polleninduced allergic rhinoconjunctivitis . Use symptomatic treatment grass polleninduced allergic rhinoconjunctivitis . Positive skin prick test response ( wheal diameter ≥3 mm ) Phleum pratense . If asthma , daily use Inhaled corticosteroid ( ICS ) ≤400 microgram budesonide equivalent Moderate high level Phleum pratense specific IgE ( Immunoglobulin E ) ( define ≥IgE Class 2 ; ≥0.70 Kilo Units/liter ( kU/L ) ) Reduced lung function ( define FEV1 &lt; 70 % ( FEV1=Forced Expiratory Volume 1 second ) predict value adequate pharmacologic treatment ) measure Visit 1 Visit 2 Clinical history uncontrolled asthma within 3 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GRAZAX</keyword>
</DOC>